Premium
Immusorba TR and PH
Author(s) -
Hirata Noriko,
Kuriyama Toshiji,
Yamawaki Naokuni
Publication year - 2003
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1046/j.1526-0968.2003.00010.x
Subject(s) - medicine , myasthenia gravis , ligand (biochemistry) , multiple sclerosis , guillain barre syndrome , immunology , receptor
Immusorba TR (IM‐TR) and PH (IM‐PH) were developed as adsorbentswith non‐biological materials as affinity ligands to remove pathogenicautoantibodies. The adsorbents of IM‐TR and IM‐PH are polyvinylalcohol gel immobilized with tryptophan and phenylalanine as ligand, respectively.IM‐TR is clinically applied for treatment of autoimmune neurologicaldiseases such as myasthenia gravis and Guillain–Barre syndrome.IM‐PH is used for not only neurological diseases such as GBS andmultiple sclerosis but also collagen diseases such as rheumatoidarthritis (RA) and systemic lupus erythematosus (SLE). As many autoantibodieswith different specificities have been found to have similar affinitiesto the ligand of Immusorba, it is expected that Immusorba will beapplied to more diseases and contribute to the clarification ofthe mechanisms of the development of diseases by the identificationof adsorbed unknown pathogenic substances with Immusorba.